In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil
pharmaphorum is proud to announce its inaugural “The World Without Disease Summit”: a high quality, two-day event bringing together key global leaders and innovators to explore the potentia
The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), seeking approval of talqueta
Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries and feed information back to their car
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.